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Objectives To assess the cost-effectiveness of uterine artery
embolisation (UAE) and myomectomy for women with
symptomatic uterine fibroids wishing to avoid hysterectomy.
Design Economic evaluation alongside the FEMME randomised
controlled trial.
Setting 29 UK hospitals.
Population Premenopausal women who had symptomatic uterine
fibroids amenable to UAE or myomectomy wishing to avoid
hysterectomy. 254 women were randomised to UAE (127) and
myomectomy (127).
Methods A within-trial cost–utility analysis was conducted from
the perspective of the UK NHS.
Main outcome measures Quality-adjusted life years (QALYs)
measured using the EuroQoL EQ-5D-3L, combined with costs to
estimate cost-effectiveness over 2 and 4 years of follow-up.
Results Over a 2-year time horizon, UAE was associated with
higher mean costs (difference £645; 95% CI 1381 to 2580) and
lower QALYs (difference 0.09; 95% CI 0.11 to 0.04) when
compared with myomectomy. Similar results were observed over
the 4-year time horizon. Thus, UAE was dominated by
myomectomy. Results of the sensitivity analyses were consistent
with the base case results for both years. Over 2 years, UAE was
associated with higher costs (difference £456; 95% CI 1823 to
3164) and lower QALYs (difference 0.06; 95% CI 0.11 to
0.02).
Conclusions Myomectomy is a cost-effective option for the
treatment of uterine fibroids. The differences in costs
and QALYs are small. Women should be fully informed
and have the option to choose between the two
procedures.
Keywords Cost-effectiveness, economic evaluation, myomectomy,
uterine artery embolisation, uterine fibroids.
Tweetable abstract Fully informed women with uterine fibroids
should have a choice between uterine artery embolisation or
myomectomy.
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The current UK guidance from the National Institute for
Health and Clinical Excellence (NICE) on treatment for uter-
ine fibroids recommends uterine artery embolisation (UAE)
as a non-surgical alternative option for women who do not
wish to have surgery and/or who wish to preserve their fertil-
ity. Conventionally, the main approach is to recommend sur-
gical treatments (hysterectomy and myomectomy), the latter
of which conserves the uterus. Another non-invasive option
is high-intensity transcutaneous focused ultrasound
(MRgHIFU) – NICE notes that there is adequate evidence of
short-term efficacy, but it is only used in the UK with special
arrangements or for research purposes.1
Few studies have evaluated the cost-effectiveness of treat-
ments available for symptomatic fibroids. These studies
focused on pre-menopausal women over 25 years old until
menopause. In these studies, UAE2–10 was compared with
MRgHIFU,2,4,5,7,10 myomectomy,2,4,6,7,9,10 hysterec-
tomy2,3,5–10 and pharmacotherapy.7 Cost-effectiveness analy-
ses were typically comprised of model-based approaches,
evaluating costs and quality-adjusted life years (QALYs).
Time horizons of 5 years,4,6,9 11 years ending at meno-
pause2,3,5,8 and lifetime7 were considered. Four evalua-
tions3–5,7 were performed in the USA with a societal
perspective, three6,8,10 in the UK from an NHS perspective,
one9 in Hong Kong from a societal perspective, and one3
evaluation in Canada with a public-payer perspective. The
results from the economic literature vary, given differences
in settings, populations and perspectives. Economic evalua-
tions which compared MRgHIFU with other treatments con-
sidered it to be the most cost-effective treatment for treating
fibroids.2,4,5,7,10 Of the evaluations that did not consider
MRgHIFU, all remaining treatments led to an improvement
in the quality of life of women. UAE was found to dominate
(be less costly and provide better outcomes), than hysterec-
tomy3,6,8 over a short time horizon. However, over a longer
time horizon, this was not the case. It was not cost-effective
when compared with hysterectomy.6,8 Hysterectomy was
favoured over myomectomy as well.9
Given the lack of conclusive evidence comparing UAE and
myomectomy, the FEMME trial was conducted to establish
the clinical effectiveness of these procedures in women who
had symptomatic uterine fibroids and did not want to
undergo a hysterectomy. This study aims to determine the
cost-effectiveness of UAE and myomectomy by performing
an economic evaluation alongside the FEMME trial.
Methods
Overview of the study design
The FEMME trial protocol and 2-year clinical results have
been published elsewhere.11,12 Briefly, FEMME was a
multicentre, randomised trial where 254 women were ran-
domised to UAE or myomectomy. Women were eligible
for the trial if they had symptomatic uterine fibroids amen-
able to UAE or myomectomy, and excluded if they had sig-
nificant adenomyosis, any malignancy, pelvic inflammatory
disease or had had a previous open UAE or myomectomy.
A substantial number of women were not recruited into
the trial due to their preference for a particular treatment
option. The primary outcome was fibroid-related quality of
life measured by the score on the health-related quality-of-
life (HR-QoL) domain of the Uterine Fibroid Symptom
and Quality of Life (UFS-QOL) questionnaire. All patient-
reported and clinical outcomes were compared between the
two groups, under an intention-to-treat (ITT) principle, at
2 and 4 years. Two years was considered to be long enough
to evaluate the sustained benefit of the intervention on the
patient but not so short that this was confounded with
recovery from surgery. Four years was chosen to see
whether the effect, if any, was maintained over a longer
term. The FEMME trial showed that both treatments led to
an improvement in HR-QoL scores. Women in myomec-
tomy group reported higher scores than those in the UAE
group. The hospital stay was shorter in the UAE group
despite the need of re-interventions being higher. Compli-
cation rates from all initial procedures were similar.
Individual patient data from the FEMME trial were used
for the economic evaluation. The perspective of the UK
NHS over the time horizons of 2 and 4 years was taken.
The time horizon is on a par with the clinical analysis.11
Effectiveness of the procedures was defined as HR-QoL
measured by the EQ-5D-3L. Cost-effectiveness was
expressed as incremental cost per QALY, where appropri-
ate. All costs were adjusted to the price year 2018/2019. A
discount rate of 3.5% was applied to both costs and out-
comes, as recommended by the NICE.13 As cost and out-
comes that are predicted to occur in the future are valued
less than present costs, discount rate adjusts for difference
in timing of costs versus outcomes. Following an ITT prin-
ciple, missing data were imputed using multiple imputation
by chained equation (MICE) for the base case analysis, and
sensitivity analysis included a complete case analysis.
Impact of varying unit cost of procedures on the mean
total cost was also tested in the sensitivity analysis. Best
practice guidance was followed for conducting and report-
ing the cost-effectiveness analysis.13,14
Resource use, costs and health outcomes
Data on resource use and HR-QoL were collected during
the treatment and follow-up periods of the trial at baseline,
6 months, 1, 2 and 4 years (Figure 1). Resource use items
were categorised into two groups: treatment-related and
post-treatment related resource use, depending on the tim-
ing of the treatment. Treatment-related resource use items
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were recorded from the time of pre-procedure fibroid
assessment to the time participants were discharged after
initial treatment. Post-treatment related resource use items
were recorded during the period from post-discharge from
initial treatment to the follow-up time points.
For treatment-related resource use, unit costs were
assigned to the procedures according to their Healthcare
Resource Group (HRG). All initial admissions were
assumed to be as elective inpatients and all repeat proce-
dures were assumed to incur the same cost as the initial
intervention. Length of stay (LOS) was determined as the
difference between admission date and discharge date,
including these days. Additional per diem cost was assigned
to estimate costs associated with these excess bed days if
the LOS exceeded the ‘trim point’ (i.e. the expected LOS
for each HRG).15 HRG episode cost was assumed to
include any medications recorded during the procedure or
during the time in ward. Unit costs from the British
National Formulary (BNF) were applied separately to any
additional medications prescribed on discharge.16
For post-treatment related resource use, average costs of
non-elective short stay (if 2 days or fewer) and long stay
(if more than 2 days) were assigned to all readmissions
until first follow-up. Women who were not readmitted to
hospital but had complications, infections or medications
during the follow-up period were assumed to have
attended outpatient clinics. Inpatient admissions and out-
patient clinic visits data recorded by hospital staff and data
completed by the participants during the same period (first
follow-up at 6 months) were cross-checked to prevent dou-
ble counting of resource use. All women who received re-
interventions for fibroid removal during the follow-up
period were assumed to be performed as elective inpatients.
Complications during treatment period or post-treatment
period were assumed to be captured by the number of hos-
pital admissions and associated excess bed days that were
recorded alongside the complications, in order to avoid
double counting.
Unit costs were valued using the NHS Reference Costs,17
Personal Social Services Resource Unit (PSSRU)18 and
BNF.16 All costs were expressed in UK pounds sterling (£)
for the price year 2018/2019 using the NHS Cost Inflation
Index (NHSCII). Total costs per patient were calculated by
assigning unit costs to within-trial resource use for each
patient. Further information on resource use items, unit
costs and their sources are presented as supporting infor-
mation (Table S1).
Patient-reported HR-QoL was measured using the EQ-
5D-3L at various time points (baseline, 6 months, 1, 2 and
4 years). A standard UK value set was applied on the
responses to calculate health utilities.19 The utility values
were then used to calculate QALYs for each participants
using the area under the curve (AUC) method which con-
siders linearity in utilities obtained at different time
points.20 Subsequently, QALYs over 2 years and over
4 years were estimated.
Missing data
The following resource use assumptions were made for
analysis:
 Medication: (1) median duration of treatment was
assumed where data on treatment duration were missing;
(2) standard BNF dose was assumed where data on
dosages were missing.
Figure 1. Resource use and HR-QoL data collection schedule.
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 Women who received initial fibroid assessment scans but
did not undergo any procedure, yet remained in the trial
and contributed cost or outcomes follow-up data (nine
participants in the UAE group and four in the myomec-
tomy group): (1) we did not make assumptions on addi-
tional resource use for women who had no other resource
use data throughout the study period (six in total from
both groups); for women who had no other resource use
data except from those during the follow-up (three from
UAE group); or for women who had additional fibroid
imaging but no fibroid removal re-intervention during the
follow-up (two from myomectomy group); (2) we made
the assumption that all women received fibroid imaging
before re-intervention (hysterectomy and myomectomy)
during the follow-up for those who had no resource use
related to imaging (two from UAE group).
Baseline variables and observed outcomes associated with
the probability of missingness were investigated using bino-
mial logistic regression.21 Missing data were assumed to be
missing at random (MAR) and imputed using MICE.22
MICE was performed on participants who withdrew, left
follow-up, had missing resource use at the main time
points or any missing health utilities. Ten imputation data-
sets were generated with predictive mean matching. The
total cost was imputed at sub-aggregate level of treatment
and non-treatment costs and QALYs were imputed at
aggregate-level of total QALYs.
Data analysis
Our base-case analysis follows the ITT principle and was
performed post multiple imputation. Cost and QALYs data
were analysed using generalised linear models (GLM). This
is appropriate as it acknowledges the non-normal distribu-
tion of cost and outcomes data and allows specification of
a distributional family and link function determined using
the modified Park’s test and other tests.23 Cost estimation
adopted a gamma family and log link, adjusted for
women’s desire to be pregnant at the time of randomisa-
tion, the longest dimension of the largest fibroid and num-
ber of fibroids (randomisation minimisation variables used
to balance the number of women allocated to each group).
Similarly, QALYs estimation adopted a Gaussian family
and identity link, adjusted for minimisation variables as
well as any potential effect modifiers of QALYs (baseline
utilities and body mass index [BMI]). Marginal mean costs
and QALYs were then predicted using the GLM. The total
costs and QALYs difference between two groups were based
on the marginal prediction.
Incremental cost effectiveness ratio (ICER; DC/DQ) was
estimated by dividing the difference in mean total costs
(incremental cost, denoted as DC = CUAE  CMyomectomy)
by the difference in mean total QALYs (incremental
QALYs, denoted as DQ = QUAE  QMyomectomy). Cost-
effectiveness was expressed as incremental cost per QALY.
An intervention was considered to be cost-effective if it was
below the willingness-to-pay (WTP) threshold (£20,000 in
the UK).13 However, ICER can be difficult to interpret,
especially in the case of dominance (e.g. intervention being
less costly and more effective, and vice versa) where it is
negative. The NMB, a measure of the health benefit
expressed in monetary terms obtained using the estimated
ICER and a pre-defined cost-effectiveness threshold (k),
allows more intuitive interpretation of the result.23 It was
calculated using the formula, NMB = (DQ 9 k) – DC,
where k = WTP threshold. An intervention was considered
cost-effective if the NMB was positive, whereas a negative
NMB implied that an intervention should be rejected, as its
value is less than the additional cost of the benefit.
A 1000-iteration bootstrap was undertaken to quantify
for uncertainty around the incremental costs and QALYs
and the resulting ICER. Results are presented using a cost-
effectiveness plane. Cost-effectiveness acceptability curves
(CEACs) were used to present uncertainty over a range of
WTP thresholds. All analysis was conducted using STATA
version 16.0 (College Station, TX, USA).
Sensitivity analyses
We considered the impact of two scenarios on our results:
(i) complete case analysis, which assumes that data are miss-
ing completely at random (MCAR), and (ii) varying the unit
costs of procedures that took place during the initial inter-
vention and re-interventions for fibroid removal in the study
timeline. The unit cost for procedures was obtained from the
English NHS reference costs, which are based on HRG. HRG
is a case-mix of clinically similar treatments which utilise a
common set of healthcare resources.15 Thus, HRG tariffs are
a reflection of NHS average costs. They may under- or over-
estimate our procedure costs and may not have captured the
differences in NHS practice across different FEMME sites.
Therefore, a 20% increment and decrement were applied to
unit cost of procedures to account for these differences.
Results
A total of 254 eligible women were randomised to UAE
(n = 127) and myomectomy (n = 127) groups. Baseline
characteristics of the two groups were similar (Table 1).
Treatment-related resource use (Table S2) showed that not
all women received the procedure of their randomised group.
In the UAE group, 14 received myomectomy and one received
endometrial ablation (14 did not receive treatment or with-
drew from the study). In the myomectomy group, six received
UAE and eight received hysterectomy (eight did not receive
treatment or withdrew from the study). The majority of
women underwent pre-procedure imaging using MRI (71%
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UAE and 79% myomectomy). UAE was associated with a
median LOS of 2 days (IQR 2–3) compared with 4 days (IQR
3–5 days) with myomectomy. Almost all women were pre-
scribed analgesics on discharge (91% in the UAE group and
97% in the myomectomy group). Post-treatment related
resource use (Table S3) showed that women who underwent
UAE were frequently readmitted to the hospital throughout
the study period. Outpatient appointments and medications
prescribed were similar between groups. More women in the
UAE group (n = 18) received re-interventions compared with
myomectomy group (n = 8) within the first 2 years. At the
end of 4 years, 22 from the UAE group had re-intervention
compared with 13 from themyomectomy group.
Women experienced improvements in their health
domains over the follow-up period (Table S4). In particu-
lar, the improvement in the pain/discomfort and anxiety/
depression domains was greater in myomectomy group
than that observed with the UAE group. Mean utilities
increased from baseline and were greater for myomectomy
group at all follow-up time points (Table 2).
There was a low proportion of missing resource use
cases at both years (4 and 8%). The EQ-5D-3L were miss-
ing for 32 and 45% of participants in 2 years and 4 years
follow-up, respectively.
At both years, total costs were higher in women who
desired pregnancy at baseline and had longer fibroid
dimension of the largest fibroid, whereas it was lower in
those with greater number of fibroids. Total QALYs was
lower in women who desired pregnancy at baseline com-
pared with those with longer fibroid dimension of the lar-
gest fibroid and greater number of fibroids. QALYs
decreased with increasing BMI. However, these results were
not statistically significant.
The mean treatment cost for the UAE group was lower
than that of the myomectomy group (£3,064 versus £3,862;
Table 2). However, UAE was associated with a higher post-
treatment cost over 2 years follow-up compared with
myomectomy group (£4,918 versus £3,431). A similar trend
was observed with post-treatment cost over 4 years of
follow-up (£5,288 versus £4,151). The total mean cost
incurred over 2 years in UAE group was £7,958 compared
with £7,314 in the myomectomy group. The 4-year total
mean cost was £8,362 for the UAE group and £8,010 for
the myomectomy group. Over 2 years, QALYs in the UAE
group was 0.74 (95% CI 0.70–0.78) compared with 0.83
(95% CI 0.79–0.87) in the myomectomy group (Table 2).
Similarly, at 4 years, the QALYs was 0.73 (95% CI 0.69–
0.76) in the UAE group and 0.82 (95% CI 0.79–0.87) in
the myomectomy group.
UAE was dominated by myomectomy. UAE was associated
with higher costs (£645 difference; 95% CI 1381 to 2580)
and lower QALYs (0.09 difference; 95% CI 0.11 to 0.04)
compared with myomectomy over a time horizon of 2 years.
Similarly, at 4 years, UAE was associated with higher costs
(£352 difference; 95% CI 1825 to 2528), and lower QALYs
(0.09 difference; 95% CI0.12 to0.05).
The cost-effectiveness plane (Figure 2) shows the uncer-
tainty associated with the incremental mean differences of
costs and QALYs in form of bootstrapped point estimates.
There is little uncertainty that UAE is associated with lower
QALYs when compared with myomectomy. There is some
uncertainty around the magnitude of difference in costs
between the two treatments. The CEACs confirm that
myomectomy had higher probability (98% at 2 years; 96%
at 4 years) of being cost-effective compared with UAE at
WTP thresholds of £20,000 and higher (Figure 2).
The results were mirrored in the complete case analysis
(Table S5) performed as a scenario in sensitivity analyses.
UAE arm had lower treatment cost compared with
myomectomy arm (£3,073 versus £3,870) but higher non-
treatment costs over 2 years (£4,663 versus £3,384) and
4 years (£5,057 versus £4,127), respectively. UAE was asso-
ciated with higher costs (£456 difference; 95% CI 1823 to
3164) and lower QALYs (0.06 difference; 95% CI 0.11
to 0.02) over a time horizon of 2 years. Similar results
were observed over a time horizon of 4 years. The differ-
ences were not statistically significant. Difference in QALYs







Age, mean (SD), n 40.2 (6.55) 42.7 (6.4)
Ethnic group
White 59 (46%) 57 (45%)
Black 48 (38%) 54 (43%)
South Asian 10 (8%) 5 (4%)
Mixed 6 (5%) 8 (6%)
Other 4 (3%) 3 (2%)
BMI (kg/m2), mean (SD) 28.2 (6.2) 28.1 (5.3)
Obstetrics history and fibroid characteristics
Desiring pregnancy at
time of randomisation
61 (48%) 61 (48%)
Longest dimension of largest fibroid, cm
≤7 64 (50%) 64 (50%)
>7 63 (50%) 63 (50%)
Mean (SD) 7.6 (3.2) 7.7 (4.2)
Number of fibroids
1–3 84 (66%) 84 (66%)
4–10 37 (29%) 37 (29%)
>10 6 (5%) 6 (5%)
Median [IQR] 2 (1–5) 2 (1–5)
EQ-5D-3L, mean (SD)
Baseline 0.62 (0.34) 0.63 (0.32)
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was 0.06 for both years. Additionally, the sensitivity anal-
ysis varying costs of procedures provided results consistent
to the base-case (Table S6). UAE was associated with
higher costs and lower QALYs. Though ICER is not
reported in this case, we observed a change in its magni-
tude depending on a 20% increment and decrement
applied on the unit costs of procedures (Figure S6).
Discussion
Main findings
UAE was associated with higher costs and lower QALYs
when compared with myomectomy over the 2- and 4-year
time horizons. The difference in costs was small (£645 and
£352 over the 2- and 4-year time horizons, respectively).
The difference in QALYs over both time horizons was 0.09.
The primary drivers of cost were GP visits, outpatient
appointments and inpatient admissions during the follow-
ups, including those associated with re-interventions for
fibroid removal. As the QALY combines the impact of
treatment on mortality and morbidity into a single index,
the difference of 0.09 can be interpreted as a gain of
33 days of perfect health in women who underwent
myomectomy. The greater improvement in pain/discomfort
and anxiety/depression domains of the EQ-5D-3L observed
in myomectomy group was the primary driver of QALYs
Table 2. Base-case analysis results
EQ-5D-3L follow-up results
UAE Myomectomy
Mean (SD) Mean (SD)
6 months 0.77 (0.30) 0.85 (0.17)
1 year 0.77 (0.30) 0.85 (0.23)
2 years 0.80 (0.29) 0.88 (0.20)
4 years 0.79 (0.30) 0.90 (0.16)
Breakdown of total cost components
UAE Myomectomy
Cost (SD) 95% CI Cost (SD) 95% CI
Treatment cost* £3,064 (80) 2906–3222 £3,862 (99) 3667–4056
Post-treatment cost over 2 years* £4,918 (939) 3076–6759 £3,431 (633) 2191–4671















































All monetary units have been rounded to the nearest pound.
CI, confidence interval; ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit; QALYs, quality-adjusted life years; SD, standard
deviation.
*Cost component for total cost.
**ICERs and NMB are not normally calculated when an intervention is dominated by its comparator. However, we present it for completeness.
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difference. Myomectomy had 98 and 96% probability of
being cost-effective at 2 and 4 years, respectively, when
compared with UAE at WTP thresholds of £20,000.
Strengths and limitations
This economic evaluation is based on the largest multicen-
tre RCT comparing UAE with myomectomy, which
adhered to the good practice guidelines set out by NICE.13
However, the cost–utility approach does not consider
patient preference. The potential trade-off between addi-
tional QALYs associated with myomectomy, and the poten-
tial benefits of avoiding a surgical procedure associated
with UAE is not known.
Interpretation
Our results are in line with those of existing studies which
compared UAE and myomectomy. These studies reported
that UAE is dominated by myomectomy4,6,9 even when
productivity costs were included.4 Moreover, UAE is only
dominated by myomectomy over the longer term.5,8 In the
short term, UAE had lower costs due to shorter procedural
time, shorter length of hospital stays and faster resumption
of usual activities.24,25 Our 2-year result confirms that UAE
had a lower treatment cost compared with myomectomy.
The LOS is the key driver of treatment cost, which was
captured only during the period from pre-procedure
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Figure 2. Cost-effectiveness planes and CEACs for 2 and 4 years.
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observed in myomectomy group than the UAE group (me-
dian 4 days compared with 2 days). Though the definition
of ‘long term’ differs across the studies, the increase in
resource use and costs, albeit only slight in QALYs, was
seen in UAE group after the first year of treatment.5 The
reason behind this continuous accumulation of cost in the
long term related to UAE was an increased rate of re-
intervention in UAE group after the first year.8 Indeed, our
results confirmed that women in the UAE group had more
re-intervention over the follow-up periods. In our study,
the majority of the post-treatment costs were accrued
within 2 years; only a small amount of additional post-
treatment costs incurred between the 2 and 4 years.
Though we did not calculate the cost of complications sep-
arately, it was captured within our treatment and post-
treatment costs. Thus, we can be confident that women in
the UAE group incurred greater post-treatment costs com-
pared with women in the myomectomy group due to
greater utilisation of healthcare resources, including those
associated re-interventions for fibroid removal. This justi-
fies the higher post-treatment costs, which are based on
costs accumulated after discharge till the end of follow-up
in the UAE group of our study.
Conversely, some studies obtained different results in
terms of cost-effectiveness.2,7 In those studies, myomec-
tomy was instead dominated by UAE. Findings reported
mean costs and mean QALYs of UAE compared with
myomectomy to be $28,892 versus $35,057 (with QALYs
17.39 versus 17.31)7 and $11,320.76 versus $13,399.09 (with
QALYs 6.282 versus 6.229)2. Here, the difference in QALYs
was marginal.
It should be noted that any comparison of the present
study with existing studies must be interpreted with cau-
tion as the studies differ in terms of settings, population,
perspectives and their method of analysis, including
assumptions related to treatments, resource use, costs and
outcomes. For instance, the dissimilarity in findings
between the above-mentioned studies and our study might
be due to the former being conducted in premenopausal
women in the USA and Canada from a societal and provi-
der perspective, respectively. These studies also used a vari-
ety of clinical literature to support their assumptions. For
example, the length of stay was obtained from a retrospec-
tive review conducted on women of reproductive age.2 Due
to this, a caveat that the results were extremely sensitive to
several parameters and assumptions was added.
There are also other reasons that support the caution we
used in the interpretation and comparison of results. For
example, myomectomy was frequently analysed with hys-
terectomy or only considered as a treatment option when
less invasive methods failed to improve symptoms. No dis-
tinction was made between multiple treatment comparators
in some cases. For example, a study grouped UAE,
myomectomy and hysterectomy as ‘current treatment’ for
comparison with MRgHIFU and assumed that 25, 25 and
50% of women were allocated to the grouped treatments,
respectively.10 Moreover, treatment costs were assumed to
be the same for all ‘current treatment’, and HR-QoL fol-
lowing successful treatment was assumed to be the same
for MRgHIFU and ‘current treatment’. Previous studies
focused on applying disutilities rather than cost to post-
treatment complications as they assumed that patients
would not experience significantly costly complications
after discharge.26 The majority of other economic evalua-
tions were comprised of model-based analysis deriving evi-
dence from the literature, especially non-randomised
studies, which sometimes present inconsistent and conflict-
ing findings on the effectiveness and safety of the treat-
ments.
Our cost–utility assessment establishes that UAE is dom-
inated by myomectomy and therefore would not be
deemed a cost-effective alternative to displace myomec-
tomy. The cost differences were small and both treatments
led to an improvement in the quality of life. A greater
improvement in the quality of life was associated with
myomectomy. However, the cost–utility analysis framework
restricts us from taking into account any potential prefer-
ence for a less invasive procedure. Some women may place
added value on a non-surgical procedure compared with a
surgical procedure for various personal reasons.
Our result does not influence the choice between UAE
and MRgHIFU, another non-surgical procedure, as the lat-
ter is only used in the UK by special arrangements or for
research purposes. Once it becomes more mainstream, it
will be possible to conduct appropriate economic evalua-
tion comparing the two treatments. Therefore, women
seeking to undergo treatments other than hysterectomy
should have the option to choose between UAE and
myomectomy, provided they are fully informed.
Conclusion
UAE was dominated by myomectomy and would not be
considered a cost-effective alternative to displace myomec-
tomy from the perspective of the UK NHS. However, the
cost–utility approach that has been adopted here does not
consider any potential preference for less invasive proce-
dures for the treatment of symptomatic uterine fibroids.
Hence, given the small difference in costs between the two
procedures, fully informed patient preference should be
taken into account and women should have the option to
choose between the two procedures. Future research should
focus on methods to quantify fully informed patient prefer-
ences and incorporate it into subsequent economic analyses
of medical, surgical and non-surgical interventions for uter-
ine fibroids.
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